Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FURIN | P09958 | 3/20 | 0.39 |
| ▸ | SIRT2 | Q8IXJ6 | 8/20 | 0.37 |
| ▸ | SIRT1 | Q96EB6 | 7/20 | 0.37 |
| ▸ | SIRT3 | Q9NTG7 | 3/20 | 0.37 |
| ▸ | SIRT5 | Q9NXA8 | 3/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23286090 | 0.90 | HTT (0.41) | FURINSIRT2SIRT1SIRT3SIRT5 | |
| SCHEMBL23680461 | 0.88 | MMP3 (0.42) | FURINSIRT2SIRT1SIRT3SIRT5 | |
| SCHEMBL23680462 | 0.86 | CTSL (0.45) | SIRT2SIRT1SIRT3SIRT5 | |
| SCHEMBL20328120 | 0.84 | CA2 (0.44) | FURINSIRT5MEN1KMT2A | |
| SCHEMBL21155227 | 0.82 | HDAC1 (0.51) | FURINSIRT2SIRT1SIRT3 | |
| SCHEMBL23286092 | 0.82 | SIRT2 (0.43) | FURINSIRT2SIRT1SIRT3SIRT5 | |
| SCHEMBL23286091 | 0.81 | HTT (0.41) | HTTMEN1LMNAKMT2A | |
| SCHEMBL20966573 | 0.80 | SPHK1 (0.41) | FURIN | |
| SCHEMBL23680473 | 0.79 | HTT (0.40) | FURINSIRT2SIRT1SIRT3SIRT5 | |
| SCHEMBL23286075 | 0.79 | NPY4R (0.45) | SIRT2SIRT1SIRT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210230218-A1 | OLIGOPEPTIDE LINKER INTERMEDIATE AND PREPARATION METHOD THEREOF | MABPLEX INTERNATIONAL, LTD. (CN) | 2021-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210230218-A1 | OLIGOPEPTIDE LINKER INTERMEDIATE AND PREPARATION METHOD THEREOF | VIP, DNPEP, PREP | FURIN 15/4885SIRT2 3512/4885SIRT1 2709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.